What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Tuberculosis
- Disease
His scientific interests lie mostly in Tuberculosis, Surgery, Immunology, Mycobacterium tuberculosis and Internal medicine.
Peter R. Donald interconnects Pharmacokinetics and Pediatrics in the investigation of issues within Tuberculosis.
His Surgery research includes themes of Pulmonary tuberculosis, Disease and Intensive care medicine.
He combines subjects such as Antibiotics, Rifampicin and Dose–response relationship with his study of Immunology.
His Mycobacterium tuberculosis study integrates concerns from other disciplines, such as Miliary tuberculosis and Epidemiology.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Delamanid and Standard treatment.
His most cited work include:
- The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. (517 citations)
- Tuberculous meningitis: a uniform case definition for use in clinical research (423 citations)
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial (319 citations)
What are the main themes of his work throughout his whole career to date?
Tuberculosis, Pediatrics, Internal medicine, Surgery and Isoniazid are his primary areas of study.
The Tuberculosis study combines topics in areas such as Pharmacokinetics, Pharmacology and Immunology.
In his study, Chemoprophylaxis is strongly linked to Incidence, which falls under the umbrella field of Pediatrics.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Pyrazinamide and Endocrinology.
His studies in Pyrazinamide integrate themes in fields like Ethionamide and Ethambutol.
His Isoniazid research is multidisciplinary, relying on both Antibacterial agent, Rifampicin and Drug resistance.
He most often published in these fields:
- Tuberculosis (63.05%)
- Pediatrics (31.53%)
- Internal medicine (27.80%)
What were the highlights of his more recent work (between 2011-2020)?
- Tuberculosis (63.05%)
- Pharmacokinetics (17.29%)
- Pediatrics (31.53%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Tuberculosis, Pharmacokinetics, Pediatrics, Pharmacology and Internal medicine.
His biological study spans a wide range of topics, including Adverse effect and Immunology.
His Pediatrics study focuses on Tuberculous meningitis in particular.
Peter R. Donald has included themes like Multiple drug resistance and Isoniazid in his Pharmacology study.
His work deals with themes such as Gastroenterology, Pyrazinamide, Moxifloxacin and Ethambutol, which intersect with Internal medicine.
His Standard treatment research is multidisciplinary, incorporating elements of Antibacterial agent and Surgery.
Between 2011 and 2020, his most popular works were:
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial (319 citations)
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance (259 citations)
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis (160 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Tuberculosis
Peter R. Donald focuses on Tuberculosis, Pharmacology, Internal medicine, Pyrazinamide and Pediatrics.
Peter R. Donald studies Bedaquiline, a branch of Tuberculosis.
His studies deal with areas such as Sputum, Isoniazid and Mycobacterium tuberculosis as well as Pharmacology.
His research in Internal medicine intersects with topics in Moxifloxacin, Surgery and Ethambutol.
Rifampicin covers he research in Pyrazinamide.
His work carried out in the field of Pediatrics brings together such families of science as MEDLINE, Disease, Severity of illness, Drug and Malnutrition.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
